INCY News & Events

Incyte announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients with moderate to severe hidradenitis suppurativa, HS. The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology, AAD, Annual Meeting, being held March 27-31, 2026, in Denver. "The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS," said Pablo Cagnoni, M.D., President and Global Head of Research and Development, Incyte. "Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical benefit with a manageable safety profile, underscoring its promise to help transform the HS treatment landscape as the first oral option. We look forward to advancing our regulatory applications in the U.S. and Europe."

Incyte announced appointments among its executive leadership team to support the Company's strategic focus and long-term growth plans. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer, CMO, and Head of Late-stage Development. Mohamed Issa, Pharm.D. has been appointed Executive Vice President, EVP, and Head of U.S. Commercial. As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

Knight Therapeutics (KHTRF) announced that its Argentine affiliate, Laboratorio LKM, and its Mexican affiliate, Grupo Biotoscana de Especialidad., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI, in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one prior line of systemic therapy. Knight entered into an exclusive supply and distribution agreement with Incyte (INCY) in September 2021 for tafasitamab across Latin America. Knight has launched MINJUVI in Brazil, Mexico and Argentina for use in combination with lenalidomide, followed by MINJUVI monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, who are not eligible for autologous stem cell transplantation. In March 2026, Knight announced the approval and launch of MINJUVI in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory FL in Brazil.